Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Clicks: 425
ID: 273036
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #51 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin. ( …
Reference Key
gr2015thesofosbuvir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Foster GR;Afdhal N;Roberts SK;Bräu N;Gane EJ;Pianko S;Lawitz E;Thompson A;Shiffman ML;Cooper C;Towner WJ;Conway B;Ruane P;Bourlière M;Asselah T;Berg T;Zeuzem S;Rosenberg W;Agarwal K;Stedman CA;Mo H;Dvory-Sobol H;Han L;Wang J;McNally J;Osinusi A;Brainard DM;McHutchison JG;Mazzotta F;Tran TT;Gordon SC;Patel K;Reau N;Mangia A;Sulkowski M; ; ;;
Journal The New England journal of medicine
Year 2015
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/26575258
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male aged middle aged young adult 80 and over Clinical Trial Phase III Randomized Controlled Trial Multicenter Study Viral Genotype drug resistance drug combinations antiviral agents / therapeutic use* chronic / complications chronic / virology antiviral agents / adverse effects hepacivirus / genetics* chronic / drug therapy* investigators=[] affs=[]) nezam afdhal graham r foster carbamates / adverse effects carbamates / therapeutic use* heterocyclic compounds 4 or more rings / adverse effects 4 or more rings / therapeutic use* sofosbuvir / adverse effects sofosbuvir / therapeutic use* liver cirrhosis / etiology viral nonstructural proteins / antagonists & inhibitors pmid:26575258 doi:10.1056/nejmoa1512612 collabauthor(name='astral-3 investigators' liver cirrhosis / drug therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.